Discoid lupus erythematosus
Therapeutic area
Immunology
Rare disease
Yes
- Definition
- A chronic, autoimmune skin condition that manifests with a red, scaling rash, most often found on the face, ears, and scalp; these lesions often lead to permanent scarring and dyspigmentation. Patients may have lesions with or without other symptoms or antibodies suggestive of systemic lupus erythematosus (SLE).
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Discoid lupus erythematosus
- Therapeutic area
- Immunology
- discoid lupus erythematosus
- DLE
- Severity
- Mild
- Immunology
- Rheumatology
- MONDO ID
- MONDO:0019558
- Parent condition
- MONDO:0015574
Related records
Broader conditions (10)
- Autoimmune disease
- Chronic cutaneous lupus erythematosus
- Connective tissue disorder
- Cutaneous lupus erythematosus
- Disease
- Disease by body system or component
- Human disease
- Immune system disorder
- Lupus erythematosus
- Rheumatic disorder
Trials (40)
- A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
- A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
- A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
- A Non-drug Study Profiling Cutaneous Lupus
- A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus
- A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies
- A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
- A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
- A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus
- A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
- A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
- A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
- Autologous Polyclonal Tregs for Lupus
- Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus
- Cutaneous Lupus Erythematosus and Elidel
- Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva
- Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions
Drugs in development (10)
- AMG-811 Phase 1
- Apremilast Phase 1
- Daxdilimab Phase 2
- Delgocitinib Phase 2
- Niacinamide Early phase 1
- Ruxolitinib Phase 2
- Secukinumab Phase 2
- Tanzisertib Phase 2
- Thalidomide Phase 2
- Tofacitinib citrate Early phase 1